WAM
GANX icon

Warberg Asset Management’s Gain Therapeutics GANX Stock Holding History

Warberg Asset Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-51,600
Closed -$65.5K – 227
2024
Q2 		$65.5K Buy
+51,600
New +$134K 0.01% 141

Other funds holding GANX

GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Warberg Asset Management's GANX Position: Q3 2024 in Review

Warberg Asset Management sold out of Gain Therapeutics (GANX) in Q3 2024, closing a stake of 51,600 shares — an estimated $65.5K sold.

Warberg Asset Management first reported a position in GANX in Q2 2024 and held it in 1 quarter. The position peaked at $65.5K in Q2 2024. 19 funds tracked by Wall St. Rank hold GANX as of Q3 2024.

  • Warberg Asset Management reported no remaining Gain Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Warberg Asset Management sold 51,600 Gain Therapeutics shares in Q3 2024, an estimated $65.5K.
  • Warberg Asset Management first reported a position in Gain Therapeutics in Q2 2024 and held it in 1 quarter.
  • Warberg Asset Management's Gain Therapeutics position peaked at $65.5K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.